Undetected and difficult to treat: multidrug resistant tuberculosis strain
Research team finds multidrug resistant TB-strain in Eswatini, that is not detected by modern diagnostic methods and has developed resistance to the new antibiotic bedaquiline.
More than a third of multidrug-resistant (MDR) tuberculosis (TB) cases in Eswatini, in Southern Africa, are caused by an outbreak strain that cannot be correctly detected by currently used molecular biological tests such as Xpert MTB/RIF. In addition, in 50% of the cases, this strain has also acquired mutations that confer resistance to two important drugs for treatment of MDR-TB, a novel drug, bedaquiline and a repurposed drug, clofazimine. The results of this work have now been published by the research team around Professor Stefan Niemann from the Research Center Borstel, Leibniz Lung Center and the German Center for Infection Research (DZIF) in the journal Genome Medicine.